niacinamide has been researched along with Alopecia in 9 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Alopecia: Absence of hair from areas where it is normally present.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is currently one of the recommended treatments for symptomatic patients with desmoid-type fibromatosis (DTF)." | 8.31 | Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose. ( Barwad, A; Dhamija, E; Gamangatti, S; Gangadharaiah, BB; Garg, V; Rastogi, S; Upadhyay, A, 2023) |
| "Clinical trials suggest that combining transcatheter arterial chemoembolization with sorafenib in patients with advanced hepatocellular carcinoma shows a superior safety and tolerability profile." | 7.80 | Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma. ( Ai, DL; Fu, JL; Li, J; Liu, CZ; Peng, XM; Wang, HM; Wang, JY; Yang, B; Yu, Q; Zhang, LZ; Zhao, Y; Zhou, L, 2014) |
| "To evaluate the efficacy and analyze the prognostic factors of sorafenib treatment in patient with unresectable primary hepatocellular carcinoma (HCC)." | 7.76 | [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma]. ( Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xie, XY; Ye, SL; Zhang, BH; Zhang, L, 2010) |
| "Sorafenib is currently one of the recommended treatments for symptomatic patients with desmoid-type fibromatosis (DTF)." | 4.31 | Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose. ( Barwad, A; Dhamija, E; Gamangatti, S; Gangadharaiah, BB; Garg, V; Rastogi, S; Upadhyay, A, 2023) |
| "Clinical trials suggest that combining transcatheter arterial chemoembolization with sorafenib in patients with advanced hepatocellular carcinoma shows a superior safety and tolerability profile." | 3.80 | Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma. ( Ai, DL; Fu, JL; Li, J; Liu, CZ; Peng, XM; Wang, HM; Wang, JY; Yang, B; Yu, Q; Zhang, LZ; Zhao, Y; Zhou, L, 2014) |
| "To evaluate the efficacy and analyze the prognostic factors of sorafenib treatment in patient with unresectable primary hepatocellular carcinoma (HCC)." | 3.76 | [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma]. ( Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xie, XY; Ye, SL; Zhang, BH; Zhang, L, 2010) |
| "The multitargeted kinase inhibitors sorafenib and sunitinib have improved treatment of solid tumours including renal cell carcinoma and hepatocellular carcinoma by offering better clinical responses." | 3.75 | Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. ( Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC, 2009) |
| "Sorafenib is an oral multikinase inhibitor approved for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer (DTC)." | 2.84 | Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. ( Ito, KI; Ito, Y; Kabu, K; Onoda, N; Sugitani, I; Takahashi, S; Tsukada, K; Yamaguchi, I, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Garg, V | 1 |
| Gangadharaiah, BB | 1 |
| Rastogi, S | 1 |
| Upadhyay, A | 1 |
| Barwad, A | 1 |
| Dhamija, E | 1 |
| Gamangatti, S | 1 |
| Ito, Y | 1 |
| Onoda, N | 1 |
| Ito, KI | 1 |
| Sugitani, I | 1 |
| Takahashi, S | 1 |
| Yamaguchi, I | 1 |
| Kabu, K | 1 |
| Tsukada, K | 1 |
| Abdel-Rahman, O | 1 |
| Fouad, M | 1 |
| Zhou, L | 1 |
| Li, J | 1 |
| Ai, DL | 1 |
| Fu, JL | 1 |
| Peng, XM | 1 |
| Zhang, LZ | 1 |
| Wang, JY | 1 |
| Zhao, Y | 1 |
| Yang, B | 1 |
| Yu, Q | 1 |
| Liu, CZ | 1 |
| Wang, HM | 1 |
| Ernst, J | 1 |
| Schäfer, V | 1 |
| Rinke, J | 1 |
| Wittig, S | 1 |
| Beck, JF | 1 |
| Ernst, T | 1 |
| Gruhn, B | 1 |
| Lee, WJ | 1 |
| Lee, JL | 1 |
| Chang, SE | 1 |
| Lee, MW | 1 |
| Kang, YK | 1 |
| Choi, JH | 1 |
| Moon, KC | 1 |
| Koh, JK | 1 |
| Zhang, L | 1 |
| Ren, ZG | 1 |
| Gan, YH | 1 |
| Wang, YH | 1 |
| Zhang, BH | 1 |
| Chen, Y | 1 |
| Xie, XY | 1 |
| Ge, NL | 1 |
| Ye, SL | 1 |
| Davis, MG | 1 |
| Thomas, JH | 1 |
| van de Velde, S | 1 |
| Boissy, Y | 1 |
| Dawson, TL | 1 |
| Iveson, R | 1 |
| Sutton, K | 1 |
| FERREIRA-MARQUES, J | 1 |
1 review available for niacinamide and Alopecia
| Article | Year |
|---|---|
Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Topics: Alopecia; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as T | 2014 |
1 trial available for niacinamide and Alopecia
| Article | Year |
|---|---|
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Neuroendocrine; Diarrhea; Drug Resistance, Neopla | 2017 |
7 other studies available for niacinamide and Alopecia
| Article | Year |
|---|---|
Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Drug-Related Side Effec | 2023 |
Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; D | 2014 |
Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AML.
Topics: Alopecia; Antineoplastic Agents; Child, Preschool; Female; Humans; Leukemia, Myeloid, Acute; Lymphoc | 2016 |
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfon | 2009 |
[Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoemb | 2010 |
A novel cosmetic approach to treat thinning hair.
Topics: Acrylates; Alopecia; Autoradiography; Caffeine; Case-Control Studies; Dimethylpolysiloxanes; Drug Co | 2011 |
[A contribution to the study of the therapeutic combination PP-B2-Fe].
Topics: Alopecia; Deficiency Diseases; Ichthyosis; Iron; Niacinamide; Pantothenic Acid; Riboflavin; Tongue; | 1950 |